Cargando…

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navitski, Anastasia, Al-Rawi, Duaa H., Liu, Ying, Rubinstein, Maria M., Friedman, Claire F., Rampal, Raajit K., Mandelker, Diana L., Cadoo, Karen, O'Cearbhaill, Roisin E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Reports and Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651772/ https://www.ncbi.nlm.nih.gov/pubmed/34926756 http://dx.doi.org/10.1016/j.gore.2021.100873

Ejemplares similares

Immunotherapy for recurrent or metastatic vulvar carcinoma: A case report and review of current guidelines
por: Praiss, Aaron, et al.
Publicado: (2022)

Primary osteosarcoma of the uterus with cardiac and pulmonary metastases
por: Abraham, Cynthia, et al.
Publicado: (2014)

Shared decision making for patients with breast and gynecologic malignancies undergoing chemotherapy associated with persistent alopecia
por: Freites-Martinez, Azael, et al.
Publicado: (2022)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas
por: Crowley, Fionnuala, et al.
Publicado: (2022)

Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting
por: Ostby, Stuart A., et al.
Publicado: (2019)

Tiktoking COVID-19 with frontline workers
por: Al-Rawi, Ahmed, et al.
Publicado: (2023)

Fusariosis in patients with hematological malignancies: Two case reports
por: Raymakers, Jord W., et al.
Publicado: (2023)

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series
por: Matsuo, Koji, et al.
Publicado: (2018)

A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome
por: Wu, Yanmei, et al.
Publicado: (2021)

Sequential Treatment by Antiviral Drugs Followed by Immunosuppressive Agents for COVID-19 Patients with Hematological Malignancy
por: Seki, Masafumi, et al.
Publicado: (2022)

A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer
por: Koneru, Mythili, et al.
Publicado: (2015)

Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers
por: Stewart, Martha E., et al.
Publicado: (2019)

Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
por: Graves, Stephen M., et al.
Publicado: (2021)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
por: Shammas, Natalie, et al.
Publicado: (2022)

Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation
por: Badiner, Nora, et al.
Publicado: (2021)

Self-control Mediates the Relationship between Psychosocial Strengths and Perceived Severity of COVID-19 among Frontline Healthcare Professionals of Pakistan: A Single Center Experience
por: Saleem, Muhammad, et al.
Publicado: (2020)

Thoracopelvic assisted movement training to improve gait and balance in elderly at risk of falling: a case series
por: Springer, Shmuel, et al.
Publicado: (2018)

Maintenance electroconvulsive therapy: Are we clutching at straws?
por: Christina, Munugapati, et al.
Publicado: (2022)

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023)

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge
por: Keane, Fergus, et al.
Publicado: (2023)

Potential utility of precision medicine for older adults with polypharmacy: a case series study
por: Finkelstein, Joseph, et al.
Publicado: (2016)

Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder
por: Heigl, Franz, et al.
Publicado: (2023)

Medication-free Alternatives for Long-term Maintenance of Bipolar Disorder: A Case Series
por: Gurevich, Michael I., et al.
Publicado: (2015)

Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): A review and novel case with dual germline SMARCA4 and BRCA2 mutations
por: Sanders, Brooke E., et al.
Publicado: (2022)

Effect of Nurse-Led Counseling on Maintenance of Healthy Lifestyle Among Outpatients Receiving Antipsychotics: Clinical Case Reports
por: Mohanty, Krutideepa, et al.
Publicado: (2021)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

Atypical Presentation of Erythroid/Megakaryocytic Leukemic Transformation of a Myeloproliferative Neoplasm Associated with Mutation and Loss of TP53
por: Chernak, Brian J., et al.
Publicado: (2020)

Real-World Case Studies Showing the Effective Use of Azelaic Acid in the Treatment, and During the Maintenance Phase, of Adult Female Acne Patients
por: Layton, Alison M, et al.
Publicado: (2023)

Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients—A Report of 10 Cases
por: De La Flor, José C., et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
por: De la Flor, José C., et al.
Publicado: (2022)

Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors
por: Zahari, Mihaela Mărioara, et al.
Publicado: (2021)

Cobimetinib‐induced “dropped head syndrome” and subsequent disease management in an Erdheim‐Chester patient
por: King, Amber C., et al.
Publicado: (2019)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures
por: McNevin, Ciara S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k1ugbubpv0nm431fih6q5m5bkc